Table 1.
Differences between transplant patients with or without malignancies.
| Malignancies NO (n = 640) YES (n =91) |
p | |||||
|---|---|---|---|---|---|---|
| 95%CI | 95%CI | |||||
| Recipient age (years) | 46 ± 16 | 51 ± 13 | 0.01 | |||
| Donor age (years) | 42 ± 17 | 38 ±16 | 0.03 | |||
| Recipient gender | n (%) | |||||
| Male | 434 (68) | 64–72 | 74 (81) | 73–89 | ||
| Female | 205 (32) | 28–36 | 17 (19) | 11–27 | 0.005 | |
| Donor gender | n (%) | |||||
| Male | 291 (49) | 44–53 | 60 (66) | 56–76 | ||
| Female | 293 (50) | 46–54 | 31 (34) | 24–44 | 0.001 | |
| Extended donor | n (%) | 212 (33) | 30–39 | 24 (26) | 17–35 | 0.06 |
| Indication for LT | n (%) | |||||
| Emphysema | 226 (35) | 31–39 | 50 (55) | 45–65 | ||
| Cystic Fibrosis | 138 (21) | 18–24 | 11 (12) | 6–18 | ||
| Pulmonary Fibrosis | 144 (22) | 19–25 | 23 (25) | 16–34 | ||
| Bronchiectasis | 21 (4) | 3–5 | 2 (2) | 0–4 | ||
| Other | 110 (18) | 15–21 | 5 (6) | 1–11 | 0.003 | |
| Donor smoking | n (%) | 108 (17) | 14–20 | 9 (10) | 4–16 | 0.62 |
| EBV D/R | n (%) | |||||
| −/− | 15 (3) | 2–4 | 7 (8) | 3–13 | ||
| −/+ | 62 (10) | 8–12 | 3 (3) | 0–6 | ||
| +/− | 54 (8) | 6–10 | 3 (3) | 0–6 | ||
| +/+ | 173 (27) | 24–30 | 32 (35) | 25–45 | ||
| ?/− | 44 (7) | 5–9 | 9 (10) | 4–16 | ||
| ?/+ | 292 (45) | 41–49 | 37 (41) | 31–51 | 0.03 | |
| Initial IS | n (%) | |||||
| CS + AZA + Steroids | 113 (17) | 14–20 | 31 (34) | 24–44 | ||
| FK+ AZA+ Steroids | 32 (5) | 4–6 | 0 | |||
| CS + MMF + Steroids | 123 (19) | 16–22 | 23 (25) | 16–34 | ||
| FK + MMF + Steroids | 372 (58) | 54–62 | 37 (41) | 31–51 | <0.001 | |
| Calcineurin inhib. based IS | n (%) | |||||
| CS | 236 (37) | 33–41 | 54 (59) | 49–69 | ||
| FK | 404 (63) | 59–67 | 37 (41) | 31–51 | <0.001 | |
| Changes in IS | n (%) | |||||
| Yes/No | 168/472 | 68/23 | <0.001 | |||
| FK to CS | 117 (18) | 15–21 | 38 (42) | 32–52 | 0.07 | |
| MMF to AZA | 51 (8) | 6–10 | 30 (33) | 23–43 | 0.01 | |
| CMV infection/disease n (%) | ||||||
| <1 month post-LT | 21 (3) | 2–4 | 11 (12) | 6–18 | 0.07 | |
| 2–3 months post-LT | 29 (5) | 4–6 | 16 (17) | 9–25 | 0.09 | |
| >3 months post-LT | 48 (8) | 6–10 | 23 (25) | 16–34 | 0.06 | |
| Total AR episodes (n) | 1.0 ± 1.14 | 1.1–1.3 | 1.1 ± 1.05 | 0.9–1.3 | 0.55 | |
| AB0 group | n (%) | |||||
| 0 | 276 (38) | 239 (37) | 33–41 | 37 (40) | 30–50 | |
| A | 354 (48) | 310 (49) | 45–53 | 44 (48) | 38–58 | |
| B | 75 (10) | 67 (10) | 8–12 | 8 (9) | 3–15 | |
| AB | 25 (3) | 24 (4) | 3–5 | 2 (3) | 0–6 | 0.02 |
| Type of LT | n (%) | 44–52 47–55 |
55–75 25–45 |
|||
| Single LT | 308 (48) | 59 (65) | ||||
| Double LT | 327 (51) | 32 (35) | ||||
| Combined liver + Double LT | 5 (0.7) | 0 | 0.01 | |||
AR: acute rejection episodes; AZA: azathioprine; CMV: cytomegalovirus; CS: cyclosporine; D/R: donor/recipient; EBV: virus Epstein-Barr; FK: tacrolimus; IS: immunosuppression; LT: lung transplantation; MMF: mycophenolate mofetil.